Day: September 27, 2022

Warehouse leader launches 350,000-square-foot GXO Direct facility in Nebraska to support Bayer Crop Science GXO has been helping Bayer grow for more than two decades GREENWICH, Conn., Sept. 27, 2022 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today celebrated the opening of a new warehouse facility with Bayer, a global leader in the life science fields of health care and nutrition, expanding the companies’ 25-year partnership. The opening event will be attended by Kearney Mayor Stanley Clouse, leaders from the Chamber of Commerce and other representatives from the local business community. Through its shared-space distribution network GXO Direct, GXO will manage warehouse support, including all shipping and receiving activities, for Bayer’s Crop Science division...

Hydro’s third quarter 2022 results will be released at 07:00 CEST (01:00 AM EST, 06:00 GMT), on Tuesday, October 25, 2022. The quarterly report and presentation slides will be available on hydro.com at the same time. Presentation in OsloHydro will host an in-person presentation and Q&A, in English, at the Felix Conference Centre at Bryggetorget 3, Oslo, at 08:30 CEST on Tuesday, October 25, 2022. The presentation, by President and CEO Hilde Merete Aasheim and CFO Pål Kildemo, can also be seen on the webcast. To attend the presentation in Oslo, please register your details via this link. There will also be a separate virtual Q&A session at 11:00 CEST. Please register your details using this link to join the conference call. Once registered, you will receive an email containing your dial in number(s) and PINs.Investor contact:Line...

MELVILLE, NY., Sept. 27, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will be participating in the Roth Inaugural Healthcare Opportunities Conference being held at The Yale Club in New York City on October 6, 2022. Company management will also be participating in one-on-one meetings throughout the conference. Mr. Alstodt will provide an update on its Phase 2 clinical trial using autologous hypoxic bone marrow-derived stem cells targeted to treat chronic lumbar disc disease. BioRestorative’s Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the Company’s autologous investigational...

AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax of 22.5 minutes AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after administration Changes in systolic blood pressure and heart rate were similar after a single dose of AQST-109 when compared to a single dose of EpiPen End-of-Phase 2 meeting with FDA scheduled for fourth quarter 2022 and remaining clinical studies will commence thereafter Company hosts conference call at 8:00 am ET on September 27, 2022WARREN, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced positive...